Guizhou Bailing Group Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002424.SZ

Guizhou Bailing Group Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.48

Guizhou Bailing Group Pharmaceutical Co., Ltd. Debt to Equity Ratio is 0.48 for the year ending December 31, 2023, a 21.08% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Guizhou Bailing Group Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.39, a -10.93% change year over year.
Guizhou Bailing Group Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.44, a -24.70% change year over year.
Guizhou Bailing Group Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.59, a -1.86% change year over year.
Guizhou Bailing Group Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.60, a 46.43% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shenzhen Stock Exchange: 002424.SZ

Guizhou Bailing Group Pharmaceutical Co., Ltd.

CEO	Mr. Min Niu
IPO Date	June 3, 2010
Location	China
Headquarters	Eco & Tech Dev Zn
Employees	6,582
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Guizhou Bailing Group Pharmaceutical Co., Ltd. researches, develops, produces, and sells Chinese medicines in China. The company provides medicines in the form of tablets, capsules, granules, syrups, pills, powders, tinctures, sprays, and ointments for cardiovascular and cerebrovascular diseases, cough, cold, pediatric, and gynecologic diseases. Guizhou Bailing Group Pharmaceutical Co., Ltd. was founded in 2005 and is based in Anshun, China.

Key trends

Past 5 years